| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.16▲ | 2.26▼ | 2.39▼ | 2.55▼ | 2.60▼ |
| MA10 | 2.19▼ | 2.46▼ | 2.55▼ | 2.55▼ | 2.98▼ |
| MA20 | 2.24▼ | 2.59▼ | 2.62▼ | 2.67▼ | 3.36▼ |
| MA50 | 2.44▼ | 2.62▼ | 2.56▼ | 3.06▼ | 2.85▼ |
| MA100 | 2.58▼ | 2.57▼ | 2.62▼ | 3.41▼ | 2.75▼ |
| MA200 | 2.63▼ | 2.65▼ | 2.79▼ | 2.97▼ | 3.58▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.006▲ | -0.062▼ | -0.065▼ | -0.002▼ | -0.182▼ |
| RSI | 34.653▼ | 13.734▼ | 19.038▼ | 27.976▼ | 33.862▼ |
| STOCH | 15.623▼ | 16.728▼ | 15.406▼ | 55.485 | 9.656▼ |
| WILL %R | -80.000▼ | -90.476▼ | -90.625▼ | -91.781▼ | -97.044▼ |
| CCI | -61.329 | -133.504▼ | -197.642▼ | -166.392▼ | -150.833▼ |
| ▼ RSI | $NRXP RSI(14) Crossed Below 30 | Set Alert |
| ▼ MACD | $NRXP MACD(12,26,9) Crossed Below Signal Line | Set Alert |
| MA | $NRXP Price Crossed Below MA(13) | Set Alert |
| MA | $NRXP Price Crossed Below MA(7) | Set Alert |
| ▲ GAP | $NRXP Open Gap Up %5 | Set Alert |
| ▲ GAP | $NRXP Open Gap Up %3 | Set Alert |
| ▲ GAP | $NRXP Open Gap Up %2 | Set Alert |
| ▼ BREAK | $NRXP Price Breaks 60 Days Low | Set Alert |
| ▼ BREAK | $NRXP Price Breaks 30 Days Low | Set Alert |
| ▼ BREAK | $NRXP Price Breaks 20 Days Low | Set Alert |
| ▼ BREAK | $NRXP Price Breaks 10 Days Low | Set Alert |
|
Friday, October 30, 2026 01:30 AM
NRx aims to return sterile, injectable drug manufacture to the United States and to end the current shortage of traditional glass-bottled ketamine through modern, high-volume “blow-fill-seal” ...
|
|
Thursday, October 29, 2026 02:59 AM
A live webcast of the conference call will be available on the Company’s website at https://ir.nrxpharma.com/events. Participants who are unable to join the webcast can access the conference call via ...
|
|
Monday, October 19, 2026 05:30 AM
In advance of November 10, 2026 GDUFA goal date, three commercial lots of Preservative-Free Ketamine have been successfully manufactured in compliance with “Process Validation” required under FDA ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 30/10/26 | 2.83 | 2.83 | 2.12 | 2.18 | 12,921,912 |
| 29/10/26 | 2.70 | 2.7732 | 2.615 | 2.66 | 1,760,886 |
| 28/10/26 | 2.73 | 2.7449 | 2.64 | 2.69 | 834,661 |
| 27/10/26 | 2.59 | 2.705 | 2.53 | 2.69 | 749,684 |
| 26/10/26 | 2.48 | 2.59 | 2.459 | 2.55 | 594,734 |
| 23/10/26 | 2.36 | 2.50 | 2.24 | 2.49 | 840,297 |
| 22/10/26 | 2.57 | 2.6099 | 2.36 | 2.40 | 1,051,688 |
| 21/10/26 | 2.65 | 2.70 | 2.61 | 2.63 | 526,552 |
| 20/10/26 | 2.63 | 2.77 | 2.545 | 2.62 | 1,348,553 |
| 19/10/26 | 2.815 | 2.815 | 2.6228 | 2.63 | 1,093,428 |
|
|
||||
|
|
||||
|
|